Wedbush Reiterates Outperform Rating on Beam Therapeutics Inc. (BEAM)

Market Context

Beam Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $27.76 with a market capitalization of $2.8B. The stock has gained 5.3% over the past 52 weeks.

Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Beam Therapeutics Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Beam Therapeutics Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Nov 04, 2026	Wedbush	Outperform	N/A
Oct 29, 2026	Canaccord Genuity	Buy	N/A
Oct 28, 2026	Wedbush	Outperform	N/A
Oct 15, 2026	HC Wainwright & Co.	Buy	N/A
Oct 14, 2026	Wedbush	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View BEAM Stock Page